Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma - Seite 4

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Adaptimmune Contacts 

Will Roberts
Vice President, Investor Relations
T:  [phone]  
E: [e-mail]

Juli P. Miller, Ph.D.
Associate Director, Investor Relations
T:  [phone]  
E: [e-mail]

Margaret Henry 
Head of PR 
T: [phone] 
Mob: [phone] 
E: [e-mail]

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via Globenewswire